63046-09-3

Usage

Uses

Used in Pharmaceutical Industry:
6,4'-DIHYDROXYFLAVONE is used as an inhibitor of HIV-1 integrase for its potential role in the development of antiretroviral therapies. Its ability to inhibit the integrase enzyme can help prevent the integration of the HIV virus into the host genome, thereby limiting viral replication and spread.
Used in Hormone Therapy:
6,4'-DIHDROXYFLAVONE is used as a ligand to the estrogen receptor, making it a potential candidate for hormone therapy applications. Its interaction with the estrogen receptor can help modulate hormonal balance and be utilized in the treatment of conditions related to estrogen levels.
Used in Antioxidant Formulations:
Due to its free radical scavenging properties, 6,4'-DIHYDROXYFLAVONE is used in antioxidant formulations to protect cells from oxidative damage. Its ability to neutralize free radicals can contribute to the prevention of various diseases and conditions associated with oxidative stress.
Used in Drug Delivery Systems:
6,4'-DIHYDROXYFLAVONE can be incorporated into drug delivery systems to enhance the bioavailability and therapeutic efficacy of other drugs. Its interaction with biomolecules and ability to chelate metal ions can improve the delivery and targeting of pharmaceutical agents.
Used in Nutraceutical Industry:
6,4'-DIHYDROXYFLAVONE can be used in the development of nutraceutical products due to its broad pharmacological activity and potential health benefits. Its presence in dietary supplements and functional foods can contribute to overall health and well-being.

InChI:InChI=1/C15H10O4/c16-10-3-1-9(2-4-10)15-8-13(18)12-7-11(17)5-6-14(12)19-15/h1-8,16-17H

Upstream product

• 177344-55-7 4,2',5'-trihydroxychalcone 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 133642-20-3 4-(tert-butyldimethylsilanyloxy)benzoic acid methyl ester 

Relevant academic research and scientific papers

COMPOUNDS FOR IMMUNOPOTENTIATION

Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed.

Synthesis of flavonoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues

Aldose reductase, the key enzyme of the polyol pathway, and oxidative stress are known to play important roles in the complications of diabetes. A drug with potent inhibition of aldose reductase and oxidative stress, therefore, would be a most promising drug for the prevention of diabetic complications. The purpose of this study was to develop new compounds with these dual-effects through synthesis of chalcone derivatives and by examining the structure-activity relationships on the inhibition of rat lens aldose reductase as well as on antioxidant effects. A series of 35 flavonoid derivatives were synthesized by Winget's condensation, oxidation, and reduction of appropriate acetophenones with appropriate benzaldehydes. The inhibitory activity of these derivatives on rat lens aldose reductase and their antioxidant effects, measured using Cu2+ chelation and radical scavenging activities on 1,1-diphenyl-picrylhydrazyl in-vitro, were evaluated. Their effect on sorbitol accumulation in the red blood cells, lenses and sciatic nerves of streptozotocin-induced diabetic rats was also estimated. Among the new flavonoid derivatives synthesized, those with the 2′,4′-dihydroxyl groups in the A ring such as 2,4,2′,4′-tetrahydroxychalcone (22), 2,2′,4′-trihydroxychalcone (11), 2′,4′-dihydroxy-2,4-dimethylchalcone (21) and 3,4,2′,4′-tetrahydroxychalcone (18) were found to possess the highest rat lens aldose reductase inhibitory activity in-vitro, their IC50 values (concentration of inhibitors giving 50 % inhibition of enzyme activity) being 1.6 × 10-7, 3.8 × 10-7, 4.0 × 10-7 and 4.6 × 10-7 M, respectively. All of the chalcones tested except 3, 18, 23 with o-dihydroxy or hydroquinone moiety showed a weak free radical scavenging activity. In the in-vivo experiments, however, compound 18 with o-dihydroxy moiety in the B ring showed the strongest inhibitory activity in the accumulation of sorbitol in the tissues. It also showed the strongest activity in transition metal chelation and free radical scavenging activity. Of the 35 4,2′-dihydroxyl and 2′,4′-dihydroxyl derivatives of flavonoid synthesized, including chalcone, flavone, flavanone, flavonol and dihydrochalcone, some chalcone derivatives synthesized were found to possess aldose reductase inhibition and antioxidant activities in-vitro as well as inhibition in the accumulation of sorbitol in the tissues in-vivo. 3,4,2′,4′-Tetrahydroxychalcone (18, butein) was the most promising compound for the prevention or treatment of diabetic complications.

A Short and Facile Synthetic Route to Hydroxylated Flavones. New Syntheses of Apigenin, Tricin, and Luteolin

Reaction of lithium polyanions generated from o-hydroxyacetophenones 3a-f with O-silyloxylated benzoates 2a-d gave 1-aryl-3-(2-hydroxyphenyl)-1,3-propanediones 4a-n, which on treatment with acetic acid containing 0.5percent H2SO4 at 95 - 100 deg C afforded hydroxylated flavones 5-18 in high yields (76 - 92percent).